Lisata Therapeutics Acquires Marea Therapeutics, Raises $225M

Source excerpt

EX-99.1 7 ef20082158_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement Combined company to focus on developing first-in-class next - generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 Liberty Corner, N.J., September 17, 2026 – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company , today announced that it has acquired Marea Therapeutics , Inc. (“Marea”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases . Concurrent with the acquisition, Lisata entered into a definitive purchase agreement for the sale of Series C non-voting convertible preferred stock in a private placement financing, which is expected to result in gross proceeds to Lisata of approximately $225 million before deducting placement agent and other offering expenses. The oversubscribed financing included participation from leading life sciences investors including RA Capital Management, Forbion, Third Ro

SEC 8-K